NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness
about
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasisA current analysis of chemotherapy strategies for the treatment of human African trypanosomiasisChemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosomeShould I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of CongoUntargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma bruceiASDCD: antifungal synergistic drug combination databaseFacile Synthesis and Preliminary Structure-Activity Analysis of New Sulfonamides Against Trypanosoma bruceiSleeping sickness elimination in sight: time to celebrate and reflect, but not relax.Evaluation of Antitrypanosomal Dihydroquinolines for Hepatotoxicity, Mutagenicity, and Methemoglobin Formation In VitroEvaluating 5-nitrofurans as trypanocidal agents.Syndromic algorithms for detection of gambiense human African trypanosomiasis in South SudanFrom on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules.Cyclic AMP effectors in African trypanosomes revealed by genome-scale RNA interference library screening for resistance to the phosphodiesterase inhibitor CpdAChallenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo.The diamidine diminazene aceturate is a substrate for the high-affinity pentamidine transporter: implications for the development of high resistance levels in trypanosomesEnantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.A mixed methods study of a health worker training intervention to increase syndromic referral for gambiense human African trypanosomiasis in South Sudan.Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.Induction of oxidative stress in Trypanosoma brucei by the antitrypanosomal dihydroquinoline OSU-40.GMP synthase is essential for viability and infectivity of Trypanosoma brucei despite a redundant purine salvage pathway.The Oral Antimalarial Drug Tafenoquine Shows Activity against Trypanosoma brucei.Treatment options for second-stage gambiense human African trypanosomiasis.Trypanosoma brucei S-adenosylmethionine decarboxylase N terminus is essential for allosteric activation by the regulatory subunit prozymeRepurposing strategies for tropical disease drug discovery.Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexansGenetic validation of aminoacyl-tRNA synthetases as drug targets in Trypanosoma brucei.Drug delivery systems in the treatment of African trypanosomiasis infections.Therapy of vector-borne protozoan infections in nonendemic settings.Non-genetic mechanisms communicating antibiotic resistance: rethinking strategies for antimicrobial drug design.The distribution of nifurtimox across the healthy and trypanosome-infected murine blood-brain and blood-cerebrospinal fluid barriersEvaluating 5-Nitrothiazoles as Trypanocidal Agents.Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier.Studies of genotoxicity and mutagenicity of nitroimidazoles: demystifying this critical relationship with the nitro group.Susceptibility Testing of Medically Important Parasites.Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.Distinct activation mechanisms trigger the trypanocidal activity of DNA damaging prodrugs.Integration of diagnosis and treatment of sleeping sickness in primary healthcare facilities in the Democratic Republic of the Congo.The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein.Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis.
P2860
Q21144510-B83A4781-B08C-41B9-8514-BCBFE4837DBEQ26820381-A0D4A121-ADF0-495D-ACF3-F79EEAB41BB3Q27671077-86D6E2AA-CAC4-4955-9EDC-747C8B5A9077Q28478935-78CED5D2-8AAE-4550-8D77-84096C45147CQ28483069-02EE1CD6-ACB5-48A0-980C-5DB423DE8A39Q28539135-B4D42F10-5446-4D29-A400-24564F22DC3FQ33636542-81A6974B-6D00-4ED2-8A6F-DC4FCD12EEE1Q33834069-206A6FD5-9596-4F3D-8E4C-189C07B8161EQ34498904-E6404644-A5DE-4C12-93A4-018FE176FE63Q34555495-AABF02B8-EA2E-4742-A1BB-B320CA4622FFQ34563648-16F6B97F-F4B2-4C4E-9FA7-708C7B60BCDFQ34775438-6CCB4414-B5A8-4FC7-BEAA-8CB68D520CF3Q34858517-FBB24CB4-0942-4870-83F5-E5ED7DDB7F6BQ35047661-4441AE4B-FBE8-4BE7-AAF5-2D2B83A2A164Q35080508-8B2B6A42-6489-409D-A89D-79CC70080428Q35105858-94E77053-F9FF-4F40-B29A-62578D5EECE6Q35126629-1193D6D6-27E0-46B1-92FC-7D75826AE105Q35189546-000E4F6A-B5B2-4D0B-AFD2-C369FE08B530Q35791902-EF7201C5-1025-42F3-8BF0-C9A69ADEED9BQ35941223-F7AE8C9C-153D-449B-884B-9F5A4675A33FQ35998332-487567B0-D1DA-4620-BACF-1A9E5B007007Q36076081-5AE8DBA5-F0EB-4116-BDC8-D52BAFDF2DB9Q36551049-C629980F-9BF5-4558-AB44-DF2F37F454C1Q36620918-07EE883C-D8EC-442C-B6CE-A769961E7913Q36858635-E23362DE-146C-43CB-AAAD-4E49FA275EB3Q37315680-40B8F711-45E5-476C-85B6-E64E53FDEF9BQ37723989-98DEFFBA-D58E-41B8-B5D8-5556B874955AQ37876880-FC902F6D-1938-41F9-9D82-9AB3F162A566Q37879203-4AB20D07-8B2D-4B45-BF0C-3D90301F1FDAQ38031896-4E0AFE85-3C17-4DB6-84AA-B72C47AEA52EQ38339557-69CE249A-1090-4DB7-9BE0-645455F5D937Q38367643-A95B6DA1-1C9B-4619-8AE8-E334142CCDB1Q38929360-2D364212-3256-40BC-A233-8300E34133F1Q39001919-B2311D1E-B5FB-48A5-B445-02776355C3FEQ39020376-B1F6E0C5-3FBF-469A-AA87-74F0A8B1FC01Q39223286-4C3A6AE6-391B-452B-A453-6C467C673660Q39245953-7C619500-5851-4416-8059-289DA463535CQ39254761-8F88904C-1651-4F14-9747-E5D692F4EABCQ39422104-0F9EC1A7-8FB6-4253-9665-D55A165508CEQ39715299-0CA5B9BF-48ED-4010-88FF-4A0B08791E77
P2860
NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
NECT is next: implementing the ...... ei gambiense sleeping sickness
@ast
NECT is next: implementing the ...... ei gambiense sleeping sickness
@en
NECT is next: implementing the ...... ei gambiense sleeping sickness
@nl
type
label
NECT is next: implementing the ...... ei gambiense sleeping sickness
@ast
NECT is next: implementing the ...... ei gambiense sleeping sickness
@en
NECT is next: implementing the ...... ei gambiense sleeping sickness
@nl
prefLabel
NECT is next: implementing the ...... ei gambiense sleeping sickness
@ast
NECT is next: implementing the ...... ei gambiense sleeping sickness
@en
NECT is next: implementing the ...... ei gambiense sleeping sickness
@nl
P2093
P2860
P921
P1476
NECT is next: implementing the ...... ei gambiense sleeping sickness
@en
P2093
Gerardo Priotto
Jacqueline Tong
Laurence Flevaud
Oliver Yun
P2860
P356
10.1371/JOURNAL.PNTD.0000720
P407
P5008
P577
2010-05-25T00:00:00Z